Hi Kam8, I hope Direct can be validated much faster than L. If Direct can convincingly extend the life of stage 4 cancer patients by few months, I believe it will be good start to get approval. So I think those patients with the metastatic cancers are the ones Direct would be validated on. These patients have only few months to live. Pressing needs to try to save them first.
Market Data 
Markets 
AI
